as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹233.08
Change
-8.93 (-3.69%)
Open
₹237.55
Prev. Close
₹242.01
Day High
₹239.73
Day Low
₹231.11
Volume Analysis
Traded
701,500
Delivered
132,729
Delivery %
18.92%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •High debt-to-equity ratio (1.04)
- •Low return on equity (-9.36%)
- •Below-average fundamentals quality score (42/100)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹246.79 | ₹243.26 | ₹238.17 | ₹234.64 | ₹229.55 | ₹226.02 | ₹220.93 |
| Fibonacci | ₹243.26 | ₹239.97 | ₹237.93 | ₹234.64 | ₹231.35 | ₹229.31 | ₹226.02 |
| Camarilla | ₹235.45 | ₹234.66 | ₹233.87 | ₹234.64 | ₹232.29 | ₹231.5 | ₹230.71 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+1.57%
1 Week
+2.08%
1 Month
+0.68%
3 Months
+3.0%
6 Months
+17.08%
1 Year
-7.53%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
3.05%
Net margin 1.68% × asset turnover 0.71x × equity multiplier 2.56x
Company Overview
Sector
Healthcare
Market Cap
₹2,079 Cr
ROE
-9.36%
Book Value
₹111.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Indoco Remedies Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 42/100. The strongest factor is Financial Strength (56/100), while Business Quality (26/100) is the weakest area to weigh before deciding. Notably: High debt-to-equity ratio (1.04); low return on equity (-9.36%).
TopFund Score — Fundamentals Quality
42/100 — WeakData confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company's working capital requirements have reduced from 40.8 days to 21.3 days
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of 8.25% over past five years.
- −Company has a low return on equity of -2.44% over last 3 years.
- −Earnings include an other income of Rs.137 Cr.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Promoter group bought 5,225 Indoco Remedies shares on 11-12 November 2026.
Promoter PAC disclosed purchase of 5,996 shares on 3 November 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 482 | 459 | 450 | 431 | 433 | 411 | 390 | 440 | 485 | 445 | 476 | 468 | 520 |
| Expenses + | 410 | 397 | 401 | 384 | 392 | 399 | 391 | 422 | 442 | 414 | 426 | 426 | 474 |
| Operating Profit | 71 | 63 | 49 | 48 | 40 | 12 | -1 | 18 | 43 | 32 | 50 | 41 | 46 |
| OPM % | 15.0% | 14.0% | 11.0% | 11.0% | 9.0% | 2.9% | -0.2% | 4.0% | 9.0% | 7.0% | 10.0% | 9.0% | 9.0% |
| Other Income + | 4 | -6 | 22 | 1 | 2 | 2 | 2 | 2 | 0 | -5 | 4 | 100 | 39 |
| Interest | 8 | 10 | 12 | 14 | 18 | 16 | 18 | 26 | 25 | 26 | 46 | 28 | 27 |
| Depreciation | 21 | 24 | 26 | 28 | 29 | 29 | 29 | 30 | 32 | 32 | 32 | 35 | 34 |
| Profit before tax | 46 | 23 | 33 | 7 | -5 | -31 | -46 | -37 | -14 | -31 | -25 | 78 | 24 |
| Tax % | 24.0% | 31.0% | 33.0% | 74.0% | 107.0% | -8.0% | -9.0% | -1.0% | -32.0% | -6.0% | -5.0% | 16.0% | 20.0% |
| Net Profit + | 35 | 16 | 22 | 2 | -10 | -28 | -41 | -36 | -9 | -29 | -24 | 65 | 19 |
| EPS in Rs | 4 | 2 | 2 | 0 | -1 | -3 | -4 | -4 | -1 | -3 | -2 | 7 | 2 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 11 | 15 | 5 | 1 | -10 | -11 | -13 | 2 | 12 | 8 | 22 | 6 | 7 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 854 | 1,005 | 1,071 | 1,041 | 968 | 1,107 | 1,242 | 1,541 | 1,669 | 1,817 | 1,665 | 1,845 | 1,909 |
| Expenses + | 689 | 834 | 914 | 906 | 892 | 983 | 1,017 | 1,213 | 1,381 | 1,572 | 1,565 | 1,703 | 1,740 |
| Operating Profit | 166 | 171 | 157 | 135 | 77 | 123 | 225 | 328 | 288 | 245 | 100 | 142 | 169 |
| OPM % | 19.0% | 17.0% | 15.0% | 13.0% | 8.0% | 11.0% | 18.0% | 21.0% | 17.0% | 13.0% | 6.0% | 8.0% | 9.0% |
| Other Income + | 2 | 1 | 4 | 5 | 6 | 2 | 3 | 2 | 1 | 20 | 6 | 0 | 137 |
| Interest | 11 | 12 | 6 | 24 | 21 | 26 | 22 | 14 | 25 | 38 | 66 | 122 | 127 |
| Depreciation | 47 | 61 | 63 | 68 | 72 | 71 | 73 | 79 | 71 | 92 | 114 | 126 | 133 |
| Profit before tax | 110 | 99 | 91 | 48 | -9 | 29 | 132 | 237 | 193 | 136 | -74 | -106 | 46 |
| Tax % | 24.0% | 17.0% | 15.0% | 15.0% | -69.0% | 16.0% | 30.0% | 35.0% | 26.0% | 29.0% | 5.0% | -7.0% | — |
| Net Profit + | 83 | 82 | 77 | 41 | -3 | 24 | 93 | 155 | 142 | 97 | -78 | -99 | 32 |
| EPS in Rs | 9 | 9 | 8 | 4 | 0 | 3 | 10 | 17 | 15 | 11 | -8 | -10 | 3 |
| Dividend Payout % | 18.0% | 18.0% | 19.0% | 22.0% | -95.0% | 11.0% | 15.0% | 13.0% | 15.0% | 14.0% | -2.0% | -2.0% | — |
| Sales growth | 17 | 18 | 7 | -3 | -7 | 14 | 12 | 24 | 8 | 9 | -8 | 11 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 500 | 558 | 633 | 657 | 642 | 661 | 751 | 886 | 1,010 | 1,091 | 1,004 | 921 | 1,003 |
| Borrowings + | 97 | 140 | 280 | 282 | 296 | 262 | 267 | 257 | 333 | 672 | 994 | 1,090 | 1,059 |
| Other Liabilities + | 230 | 224 | 266 | 281 | 301 | 330 | 279 | 325 | 297 | 363 | 414 | 564 | 532 |
| Total Liabilities | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,593 | 2,613 |
| Fixed Assets + | 340 | 374 | 440 | 489 | 468 | 590 | 570 | 555 | 678 | 954 | 997 | 1,193 | 1,240 |
| CWIP | 63 | 55 | 91 | 136 | 185 | 51 | 68 | 122 | 114 | 125 | 321 | 90 | 27 |
| Investments | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 9 | 1 | 1 | 15 |
| Other Assets + | 443 | 496 | 666 | 613 | 605 | 631 | 677 | 809 | 864 | 1,057 | 1,111 | 1,309 | 1,331 |
| Total Assets | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,593 | 2,613 |
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 109 | 112 | 89 | 123 | 132 | 123 | 82 | 174 | 179 | 157 | 95 | 192 |
| Cash from Investing Activity + | -88 | -111 | -171 | -135 | -104 | -56 | -67 | -121 | -208 | -433 | -339 | -102 |
| Cash from Financing Activity + | -20 | -2 | 132 | -39 | -16 | -64 | -30 | -44 | 23 | 280 | 241 | -77 |
| Net Cash Flow | 1 | 0 | 50 | -51 | 12 | 3 | -14 | 8 | -7 | 4 | -3 | 14 |
| Free Cash Flow | 20 | 15 | -100 | -15 | 39 | 64 | 6 | 49 | -27 | -269 | -257 | 91 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 81 | 82 | 72 | 98 | 177 | 103 | 45 | 66 | 84 | 76 | 112 | 139 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Others | 0.0% | 0.03% | 0.03% | 0.03% | 0.03% | 0.09% | 0.09% | 0.09% | 0.09% | 0.14% | 0.14% | 0.14% |
| Public | 20.0% | 19.92% | 21.07% | 21.27% | 21.02% | 21.02% | 20.82% | 21.6% | 21.76% | 21.9% | 22.04% | 22.66% |
| Promoters | 58.75% | 58.72% | 58.76% | 58.76% | 58.8% | 58.9% | 58.9% | 58.9% | 58.9% | 58.86% | 58.86% | 58.92% |
| FII | 1.69% | 1.92% | 1.48% | 1.7% | 1.25% | 1.24% | 1.22% | 1.25% | 1.1% | 0.94% | 1.27% | 1.64% |
| DII | 19.56% | 19.41% | 18.67% | 18.25% | 18.91% | 18.75% | 18.96% | 18.16% | 18.15% | 18.15% | 17.68% | 16.64% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Indoco Remedies Ltd. (this stock) | 2,079 | — | 2.03 | -9.36% |
| Windlas Biotech Limited | 2,067 | 31.1 | 3.64 | 12.2% |
| Venus Remedies Limited | 2,002 | 16.4 | 2.84 | 15.6% |
| Hester Biosciences Ltd | 1,992 | 33.9 | 4.26 | 15.9% |
| Beta Drugs Limited | 1,990 | 38.3 | 4.54 | 18.8% |
| Panacea Biotec Ltd | 2,171 | — | 2.6 | -2.42% |
| Sakar Healthcare Limited | 2,172 | 50.7 | 6.26 | 9.99% |
Which Mutual Funds Hold Indoco Remedies Ltd.?
Frequently Asked Questions about Indoco Remedies Ltd.
Indoco Remedies Ltd. (INDOCO) closed at ₹233.08 on NSE on 19 November 2026, down 8.93 (3.69%) from the previous close.
Indoco Remedies Ltd. trades on the NSE (National Stock Exchange of India) under the symbol INDOCO.
Indoco Remedies Ltd. has a dividend yield of 0.09%.
Indoco Remedies Ltd.'s 52-week high is ₹288.0 and its 52-week low is ₹162.0.
Indoco Remedies Ltd. has a market capitalisation of ₹2,079 crore.
Indoco Remedies Ltd. has a TopFund Quality Score of 42/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Indoco Remedies Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.